CPHI Milan 2
CPHI Milan newsletter
PCI High Potent Manufacturing
LB Bohle – 10.06.2025
Temax_Krautz

Current Edition

Current Edition

Subsection - CDMO

Examining how innovative technologies, integrated manufacturing approaches and AI are shaping manufacturing.

Continue reading

Subsection - Injectables

Exploring advances in injectable drug delivery and sterile manufacturing, designed to improve patient-centric delivery.

Continue reading

Subsection - Neurodegenerative Diseases

Exploring emerging approaches to neurodegenerative disease research and treatment.

Continue reading

Subsection - Nasal & Pulmonary

Highlighting how advances in nasal and pulmonary drug delivery, formulation, devices and analytics are enabling more complex therapies.

Continue reading

Advertisement

CPHI 2027
DDL 2026

Advertisement

Nipro August 26

Advertisement

Merxin March 2026

Advertisement

Aurisco 300×250

Advertisement

Lifecore Biomedical
News

AstraZeneca’s long-acting antibody combination treats and prevents COVID-19

Positive high-level results from the TACKLE Phase III COVID-19 treatment trial have shown that AstraZeneca’s AZD7442, a long-acting antibody (LAAB) combination, achi...
Continue Reading →
News

AiPharma forms alliance with Appili Therapeutics

Private biopharmaceutical research, development, and commercialisation company, AiPharma, has announced a strategic alliance with biopharmaceutical company Appili Th...
Continue Reading →
News

CHMP positive option for Pfizer-BioNTech COVID-19 vaccine in the EU

Pfizer and BioNTech have announced that the Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for the administration of the Pfizer-...
Continue Reading →
News

Largest COVID-19 PCR provider announces expansion of ‘cube’ labs

The UK’s largest laboratory diagnostics company, Randox, has announced a nationwide expansion of ten new adaptive ‘cube’ laboratories across Great Britain, with faci...
Continue Reading →
News

Merck announces its antiviral COVID-19 pill halves hospitalisations and deaths

Merck, known as MSD outside the United States and Canada, and Ridgeback Biotherapeutics have announced that molnupiravir (MK-4482, EIDD-2801), an investigational ora...
Continue Reading →
News

Positive topline results for Pfizer/BioNTech jab in five to 11-year-olds

Pfizer and BioNTech have announced that their COVID-19 vaccine is safe for use in children aged five to 11 years old. Results from a Phase II/III trial showed a f...
Continue Reading →
News

AdaCore’s QGen automated code generator helps develop new artificial lung equipment to treat Covid patients in only six months

Leading provider of software development and verification tools, AdaCore, has joined forces with the Eldorado Institute in Brazil and medical device manufacturer Bra...
Continue Reading →
News

UK Government terminates COVID-19 vaccine agreement with Valneva

The French speciality vaccine company, Valneva, has announced that it has received a termination notice from the UK Government in relation to the Supply Agreement fo...
Continue Reading →
Volume 13 Issue 3

Changing the Face of Infection Prevention

As we approach the 18-month mark since the onset of COVID-19, the greatest global pandemic of our times, many are turning their attention to what seems to be the nex...
Continue Reading →
News

Gov’t injects £5.4bn to support NHS England’s COVID-19 response

The government has announced an extra £5.4bn funding injection into the NHS in England in a bid to tackle backlogs caused by the COVID-19 pandemic. The funding wi...
Continue Reading →

Advertisement

MedPharm 16/07

Advertisement

Biopharma group march 2026

Advertisement

Silgan March 2026

Advertisement

Terumo 06/26

Advertisement

Scott Pharma – 25.03.2025

Advertisement

Bespak

Advertisement

Solstice

Advertisement

Bachem skyscraper
Tjoapack
Aptar – 08/01/2026